Income Statement

v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Condensed Consolidated Statements Of Operations        
Revenues, net $ 210,544 $ 187,912 $ 344,771 $ 418,325
Operating expenses:        
Cost of implants and other costs 166,665 46,185 190,015 86,638
Research and development 43,339 0 51,570 0
Selling, general and administrative 778,693 553,224 1,285,293 944,463
Termination of licensing agreement 132,804
Depreciation and amortization 8,465 795 16,854 1,368
Total operating expenses 997,162 600,204 1,543,732 1,165,273
Loss from operations (786,618) (412,292) (1,198,961) (746,948)
Other income (expenses):        
Gain on settlement of debt 285,924 285,924
Interest expense, net (459,064) (223,127) (10,220,569) (388,359)
Gain (loss) on change in fair value of derivative liability 12,263,680 (438,344) (15,897,993) (467,041)
Total other income (expenses) 12,090,540 (661,471) (25,832,638) (855,400)
Income (loss) before income taxes 11,303,922 (1,073,763) (27,031,599) (1,602,348)
Income taxes
Net Income (loss) $ 11,303,922 $ (1,073,763) $ (27,031,599) $ (1,602,348)
Net income (loss) per common share, basic $ 0.05 $ (0.01) $ (0.12) $ (0.01)
Net income (loss) per common share, diluted $ 0.02 $ (0.01) $ (0.12) $ (0.01)
Weighted average number of common shares outstanding, basic 241,730,516 165,394,501 222,279,257 165,166,479
Weighted average number of common shares outstanding, diluted 579,668,702 165,394,501 222,279,257 165,166,479

Source